ゲムシタビン塩酸塩

用途DNA 合成を阻害して細胞死を 誘発する効果があるとされています。ゲムシタビン (gemcitabine) とは、抗癌剤として用いられる含フッ素ヌクレオシドの一種である。シチジンのリボース環の2'位がフッ素2個で置換された構造を持つ。イーライリリー・アンド・カンパニーが開発し、ジェムザール（Gemzar、略号：GEM）という商品名で塩酸塩（塩酸ゲムシタビン）を上市している。ジェムザールの性状は白色～微黄白色の結晶性の粉末である。

説明Gemcitabine is a novel nucleoside analog that was launched in 1995 in the Netherlands for the treatment of non-small cell lung cancer (nsclc) and in Sweden for pancreatic cancer. Gemcitabine is a prodrug which is phosphorylated intracellularly by deoxycytadine kinase to its active forms, the di- and triphosphates which bind to DNA competitively. This insertion inhibits processes required for DNA synthesis and metabolism, the essential function for both cell replication and repair. Furthermore, gemcitabine displays an extraordinary array of self-potentiating mechanisms that increase the concentration and prolong the retention of its active nucleotides in tumor cells. The title compound has shown activity against a wide spectrum of human solid tumors including colon, mammary, breast, bladder cancers. Synergistic activity of gemcitabine with other anticancer agents such as cisplatin has been reported.